Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and young people older than 1 month and younger than 18 years of age
- People who have been diagnosed with acute lymphoblastic leukemia (a type of blood cancer) confirmed by a bone marrow test
- People whose leukemia has been identified as a specific type called B-cell ALL (B-ALL), confirmed by laboratory testing of the cancer cells
Who may not be able to join:
- People whose ALL has been classified as low-risk
- People whose leukemia cells test positive for a marker called sIgM+ (confirm with trial site)
- People diagnosed with a mixed or unclear type of acute leukemia, based on World Health Organization (WHO) or EGIL classification guidelines
- People whose ALL developed as a result of a previous condition called chronic myeloid leukemia (CML)
- People with Down's syndrome, or a significant inherited or birth-related condition that affects how an organ functions
- People whose leukemia developed as a result of a previous cancer treatment (called secondary leukemia)
- People with a known inherited immune system disorder or an inherited condition affecting the body's metabolism
- People with a heart condition present from birth that is causing the heart to not function properly
- People who have received steroid medications (glucocorticoids) for 14 days or more, or certain targeted cancer medicines called ABL kinase inhibitors for more than 7 days, within the month before joining — or any chemotherapy or radiation therapy within the 3 months before joining (emergency radiation used to relieve airway obstruction may be an exception — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Phone: +86 22 23909196
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To investigate if Group B[2*(14-day blinatumomab + HDMTX*2)] can result in noninferior event-free survival (EFS) compared to Group A [28-day blinatumomab + HDMTX*4
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.